**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM) reported that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro® protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept® (Donepezil HCl, Pfizer – NYSE: PFE), Exelon® (Rivastigmine, Novartis – NYSE: NVS), and Namenda® (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro® was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro® now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro® diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro® diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro® diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.

LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral vascular devices and implants, will present at the Canaccord Genuity 30th Annual Growth Conference at the InterContinental Hotel in Boston, MA. George W. LeMaitre, Chairman & CEO, will provide an update on the company on August 12, 2010 at 3:00 pm EDT.

LeMaitre Vascular is a leading global provider of innovative devices for the treatment of peripheral vascular disease. LeMaitre develops, manufactures, and markets disposable and implantable vascular devices to address the needs of vascular surgeons and interventionalists. LeMaitre’s diversified product portfolio consists of well-known brand name products used in arteries and veins outside of the heart.

LeMaitre Vascular expands and diversifies its product portfolio through acquisitions and internal research and development. These products are distributed through its geographically expanding sales channel. The company follows its vascular surgeon customer base as it transitions from traditional, open arterial surgery to vein surgery, dialysis surgery, and endovascular procedures. As the company has grown, it has focused increasingly on patented, differentiated product platforms.

Integra LifeSciences Holdings Corporation (Nasdaq:IART) will present at two conferences in August.

On Thursday, August 5th, 2010 at 8:30 am ET, Mr. Gerry Carlozzi, Executive Vice President and Chief Operating Officer of Integra, will present at the BMO Capital Markets 10th Annual Focus on Healthcare Conference at the Sheraton New York Hotel in New York City.

On Tuesday, August 10th, 2010 at 1:30 pm ET, Mr. Stuart Essig, President and CEO of Integra, will present at the Canaccord Genuity Global Healthcare Conference at the Intercontinental Hotel in Boston, MA. There will be no webcast for this presentation.

Integra is a fully integrated medical device company with thousands of products for the medical specialties. Integra’s objective is to develop or otherwise provide any product that will improve service to its customers. These products include both surgical implants and medical instruments for use in neurosurgery, orthopedics, and general surgery. Integra distinguishes itself, however, by emphasizing the importance of the relatively new field of regenerative medicine.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is a global medical device company dedicated to improving the quality of life for millions of patients every year. Integra’s products are used primarily in orthopedics, neurosurgery and general surgery. Headquartered in Plainsboro, New Jersey, Integra has research and manufacturing facilities throughout the world.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) . Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Tags: Disease, Integra LifeSciences, LeMaitre Vascular, medical stock, NASDAQ:IART, NASDAQ:LMAT, Power 3, Power Three, PWRM.OB, surgical implants, vascular disease

This entry was posted on Friday, July 30th, 2010 at 12:44 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.